The Obesity Drug Wars Enter a New Phase: Monthly Shots, Oral Pills, and a Challenger From Roche

Viking Therapeutics just dropped trial data that could reshape how millions of Americans take weight-loss medication: patients who switched from weekly to monthly injections of VK2735 retained an average of 85% of their weight loss, while those on every-other-week dosing held 90%. Patients sticking with weekly injections lost a remarkable 21.7% of body weight at 33 weeks — with no plateau in sight. Shares of Viking Therapeutics (VKTX) surged 36% on the...